HER2陰性乳がん治療の世界市場（～2026年）

• 英文タイトル：Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12176
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料はHER2陰性乳がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、手術、放射線、ホルモン療法/内分泌療法）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別HER2陰性乳がん治療の競争状況、市場シェア
・世界のHER2陰性乳がん治療市場：種類別市場規模 2015年-2020年（化学療法、手術、放射線、ホルモン療法/内分泌療法）
・世界のHER2陰性乳がん治療市場：種類別市場規模予測 2021年-2026年（化学療法、手術、放射線、ホルモン療法/内分泌療法）
・世界のHER2陰性乳がん治療市場：用途別市場規模 2015年-2020年（病院、クリニック）
・世界のHER2陰性乳がん治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック）
・北米のHER2陰性乳がん治療市場分析：米国、カナダ
・ヨーロッパのHER2陰性乳がん治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのHER2陰性乳がん治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のHER2陰性乳がん治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのHER2陰性乳がん治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：AstraZeneca、Bristol-Myers Squibb、Eli Lilly、Pfizer、Novartis、Pfizer、GlaxoSmithKline、Novartis、Merck、Eli Lilly
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.

Market Analysis and Insights: Global HER2-negative breast cancer Treatment Market
The global HER2-negative breast cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global HER2-negative breast cancer Treatment Scope and Market Size
HER2-negative breast cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global HER2-negative breast cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly

Market segment by Type, the product can be split into
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Market segment by Application, split into
Hosptial
Clinic

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by HER2-negative breast cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Surgery
1.4.4 Radiation
1.4.5 Hormonal therapy/endocrine therapy
1.5 Market by Application
1.5.1 Global HER2-negative breast cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hosptial
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global HER2-negative breast cancer Treatment Market Perspective (2015-2026)
2.2 Global HER2-negative breast cancer Treatment Growth Trends by Regions
2.2.1 HER2-negative breast cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 HER2-negative breast cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 HER2-negative breast cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key HER2-negative breast cancer Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top HER2-negative breast cancer Treatment Players by Market Size
3.1.1 Global Top HER2-negative breast cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global HER2-negative breast cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global HER2-negative breast cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global HER2-negative breast cancer Treatment Market Concentration Ratio
3.2.1 Global HER2-negative breast cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by HER2-negative breast cancer Treatment Revenue in 2019
3.3 HER2-negative breast cancer Treatment Key Players Head office and Area Served
3.4 Key Players HER2-negative breast cancer Treatment Product Solution and Service
3.5 Date of Enter into HER2-negative breast cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global HER2-negative breast cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global HER2-negative breast cancer Treatment Market Size by Application (2015-2020)
5.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America HER2-negative breast cancer Treatment Market Size (2015-2020)
6.2 HER2-negative breast cancer Treatment Key Players in North America (2019-2020)
6.3 North America HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
6.4 North America HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe HER2-negative breast cancer Treatment Market Size (2015-2020)
7.2 HER2-negative breast cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
7.4 Europe HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

8 China
8.1 China HER2-negative breast cancer Treatment Market Size (2015-2020)
8.2 HER2-negative breast cancer Treatment Key Players in China (2019-2020)
8.3 China HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
8.4 China HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan HER2-negative breast cancer Treatment Market Size (2015-2020)
9.2 HER2-negative breast cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
9.4 Japan HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia HER2-negative breast cancer Treatment Market Size (2015-2020)
10.2 HER2-negative breast cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

11 India
11.1 India HER2-negative breast cancer Treatment Market Size (2015-2020)
11.2 HER2-negative breast cancer Treatment Key Players in India (2019-2020)
11.3 India HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
11.4 India HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America HER2-negative breast cancer Treatment Market Size (2015-2020)
12.2 HER2-negative breast cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca HER2-negative breast cancer Treatment Introduction
13.1.4 AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb HER2-negative breast cancer Treatment Introduction
13.2.4 Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
13.3.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer HER2-negative breast cancer Treatment Introduction
13.4.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis HER2-negative breast cancer Treatment Introduction
13.5.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer HER2-negative breast cancer Treatment Introduction
13.6.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 GlaxoSmithKline
13.7.1 GlaxoSmithKline Company Details
13.7.2 GlaxoSmithKline Business Overview
13.7.3 GlaxoSmithKline HER2-negative breast cancer Treatment Introduction
13.7.4 GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.7.5 GlaxoSmithKline Recent Development
13.8 Novartis
13.8.1 Novartis Company Details
13.8.2 Novartis Business Overview
13.8.3 Novartis HER2-negative breast cancer Treatment Introduction
13.8.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.8.5 Novartis Recent Development
13.9 Merck
13.9.1 Merck Company Details
13.9.2 Merck Business Overview
13.9.3 Merck HER2-negative breast cancer Treatment Introduction
13.9.4 Merck Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.9.5 Merck Recent Development
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview
13.10.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
13.10.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.10.5 Eli Lilly Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. HER2-negative breast cancer Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by HER2-negative breast cancer Treatment Revenue
Table 3. Ranking of Global Top HER2-negative breast cancer Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Surgery
Table 7. Key Players of Radiation
Table 8. Key Players of Hormonal therapy/endocrine therapy
Table 9. Global HER2-negative breast cancer Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global HER2-negative breast cancer Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global HER2-negative breast cancer Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global HER2-negative breast cancer Treatment Market Share by Regions (2015-2020)
Table 13. Global HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global HER2-negative breast cancer Treatment Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. HER2-negative breast cancer Treatment Market Growth Strategy
Table 19. Main Points Interviewed from Key HER2-negative breast cancer Treatment Players
Table 20. Global HER2-negative breast cancer Treatment Revenue by Players (2015-2020) (Million US$)
Table 21. Global HER2-negative breast cancer Treatment Market Share by Players (2015-2020)
Table 22. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2019)
Table 23. Global HER2-negative breast cancer Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players HER2-negative breast cancer Treatment Product Solution and Service
Table 26. Date of Enter into HER2-negative breast cancer Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 29. Global HER2-negative breast cancer Treatment Market Size Share by Type (2015-2020)
Table 30. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2021-2026)
Table 31. Global HER2-negative breast cancer Treatment Market Size Share by Application (2015-2020)
Table 32. Global HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 33. Global HER2-negative breast cancer Treatment Market Size Share by Application (2021-2026)
Table 34. North America Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 35. North America Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 36. North America HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 37. North America HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 38. North America HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. North America HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 40. Europe Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 42. Europe HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. Europe HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 44. Europe HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. Europe HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 46. China Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 47. China Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 48. China HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. China HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 50. China HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. China HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 52. Japan Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 54. Japan HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. Japan HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 56. Japan HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. Japan HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 60. Southeast Asia HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 62. Southeast Asia HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 64. India Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 65. India Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 66. India HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. India HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 68. India HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. India HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 70. Central & South America Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)
Table 72. Central & South America HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America HER2-negative breast cancer Treatment Market Share by Type (2015-2020)
Table 74. Central & South America HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America HER2-negative breast cancer Treatment Market Share by Application (2015-2020)
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Product
Table 79. AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 80. AstraZeneca Recent Development
Table 81. Bristol-Myers Squibb Company Details
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Product
Table 84. Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 85. Bristol-Myers Squibb Recent Development
Table 86. Eli Lilly Company Details
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Product
Table 89. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 90. Eli Lilly Recent Development
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Product
Table 94. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 95. Pfizer Recent Development
Table 96. Novartis Company Details
Table 97. Novartis Business Overview
Table 98. Novartis Product
Table 99. Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 100. Novartis Recent Development
Table 101. Pfizer Company Details
Table 102. Pfizer Business Overview
Table 103. Pfizer Product
Table 104. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 105. Pfizer Recent Development
Table 106. GlaxoSmithKline Company Details
Table 107. GlaxoSmithKline Business Overview
Table 108. GlaxoSmithKline Product
Table 109. GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 110. GlaxoSmithKline Recent Development
Table 111. Novartis Business Overview
Table 112. Novartis Product
Table 113. Novartis Company Details
Table 114. Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 115. Novartis Recent Development
Table 116. Merck Company Details
Table 117. Merck Business Overview
Table 118. Merck Product
Table 119. Merck Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 120. Merck Recent Development
Table 121. Eli Lilly Company Details
Table 122. Eli Lilly Business Overview
Table 123. Eli Lilly Product
Table 124. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)
Table 125. Eli Lilly Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HER2-negative breast cancer Treatment Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Surgery Features
Figure 4. Radiation Features
Figure 5. Hormonal therapy/endocrine therapy Features
Figure 6. Global HER2-negative breast cancer Treatment Market Share by Application: 2020 VS 2026
Figure 7. Hosptial Case Studies
Figure 8. Clinic Case Studies
Figure 9. HER2-negative breast cancer Treatment Report Years Considered
Figure 10. Global HER2-negative breast cancer Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global HER2-negative breast cancer Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global HER2-negative breast cancer Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global HER2-negative breast cancer Treatment Market Share by Players in 2019
Figure 15. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by HER2-negative breast cancer Treatment Revenue in 2019
Figure 17. North America HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

以下、関連資料のご紹介

トリプルネガティブ乳がん治療の世界市場（～2026年）

Global Triple-Negative Breast Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04900 2020年11月20日 90Pages
当調査資料はトリプルネガティブ乳がん治療のグローバル市場について調査・分析したレポートです。種類別（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）市場規模、用途別（病院薬局、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...

乳癌治療の世界市場（～2026年）

Global Breast Cancer Therapeutic Market Size, Status and Forecast 2020-2026
MRC2-11QY11194 2020年11月25日 96Pages
当調査資料は乳癌治療のグローバル市場について調査・分析したレポートです。種類別（フェーズI治療、フェーズII治療、フェーズIII治療）市場規模、用途別（病院、外来手術センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

HER2抗体の世界市場（～2026年）

Global HER2 Antibodies Market Size, Status and Forecast 2020-2026
MRC2-11QY12175 2020年11月25日 90Pages
当調査資料はHER2抗体のグローバル市場について調査・分析したレポートです。種類別（トラスツズマブ、ラパチニブ、アド-トラスツズマブエムタンシン、ペルツズマブ、エベロリムス）市場規模、用途別（病院薬局、小売薬局、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

乳癌スクリーニング検査の世界市場（～2026年）

Global Breast Cancer Screening Tests Market Size, Status and Forecast 2020-2026
MRC2-11QY11193 2020年11月25日 92Pages
当調査資料は乳癌スクリーニング検査のグローバル市場について調査・分析したレポートです。種類別（身体検査、実験室検査、画像検査、遺伝子検査）市場規模、用途別（研究所、癌研究所、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、...

乳癌リキッドバイオプシーの世界市場（～2026年）

Global Breast Cancer Liquid Biopsy Market Size, Status and Forecast 2020-2026
MRC2-11QY11191 2020年11月25日 99Pages
当調査資料は乳癌リキッドバイオプシーのグローバル市場について調査・分析したレポートです。種類別（循環腫瘍細胞（CTC）、無細胞DNA（CfDNA）、細胞外小胞（EV）、その他循環バイオマーカー）市場規模、用途別（病院、診断センター、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

転移性がん治療の世界市場（～2026年）

Global Metastatic Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12665 2020年11月25日 91Pages
当調査資料は転移性がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、生物学的標的療法、乳腺手術、ホルモン療法）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

乳癌モノクローナル抗体の世界市場（～2026年）

Global Breast Cancer Monoclonal Antibodies Market Size, Status and Forecast 2020-2026
MRC2-11QY11192 2020年11月25日 125Pages
当調査資料は乳癌モノクローナル抗体のグローバル市場について調査・分析したレポートです。種類別（ネイキッドMAb、コンジュゲートMAb）市場規模、用途別（病院、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...

下咽頭がん治療の世界市場（～2026年）

Global Hypopharyngeal Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12289 2020年11月25日 92Pages
当調査資料は下咽頭がん治療のグローバル市場について調査・分析したレポートです。種類別（ガネテスピブ、PGV-001、ニモツズマブ、CDX-3379、その他）市場規模、用途別（外来患者、入院患者）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

甲状腺がん治療の世界市場（～2026年）

Global Thyroid Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04851 2020年11月20日 92Pages
当調査資料は甲状腺がん治療のグローバル市場について調査・分析したレポートです。種類別（手術、ヨウ素療法、体外照射療法、サイロキシン治療、化学療法、薬物）市場規模、用途別（病院、腫瘍学センター、病院薬局、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

非血液がん治療の世界市場（～2026年）

Global Non-Hematological Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04000 2020年11月20日 97Pages
当調査資料は非血液がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、手術、放射線療法、その他）市場規模、用途別（病院、腫瘍治療センター、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

トリプルネガティブ乳がん治療の世界市場（～2026年） Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Triple-Negative Breast Cancer Treat…
乳癌治療の世界市場（～2026年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Breast Cancer Therapeutic Scope and Market Size Breast Cancer T…
転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…
HER2抗体の世界市場（～2026年） The demand of HER2 Antibodies is increasing, and primarily gaining from growing awareness regarding the prevalence of HER2 positive breast cancer. Market Analysis and Insights: Global HER2 Antibodies Market The global HER2 Antibodies market size is projected to reach US$ 8543.4 million by 2026, from…
非血液がん治療の世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…